Alnylam's Transthyretin Amyloidosis Drug Gets Positive Opinion From EU Agency

 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). ATTR-CM is a debilitating, rapidly progressive and potentially fatal disease for which there are limited treatment options. Vutrisiran is currently approved in the European Union (EU) under the brand name AMVUTTRA® for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

https://www.streetinsider.com/Corporate+News/Alnylam+Pharma+%28ALNY%29+Receives+Positive+CHMP+Opinion+for+Vutrisiran+for+the+Treatment+of+ATTR+Amyloidosis+with+Cardiomyopathy/24694042.html